GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Connect Biopharma Holdings Ltd (NAS:CNTB) » Definitions » Notes Receivable

CNTB (Connect Biopharma Holdings) Notes Receivable : $0.00 Mil (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Connect Biopharma Holdings Notes Receivable?

Connect Biopharma Holdings's Notes Receivable for the quarter that ended in Mar. 2025 was $0.00 Mil.


Connect Biopharma Holdings Notes Receivable Historical Data

The historical data trend for Connect Biopharma Holdings's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Connect Biopharma Holdings Notes Receivable Chart

Connect Biopharma Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Notes Receivable
Get a 7-Day Free Trial - - - - -

Connect Biopharma Holdings Quarterly Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Mar24 Jun24 Dec24 Mar25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Connect Biopharma Holdings Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Connect Biopharma Holdings Notes Receivable Related Terms

Thank you for viewing the detailed overview of Connect Biopharma Holdings's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Connect Biopharma Holdings Business Description

Traded in Other Exchanges
N/A
Address
3580 CARMEL MOUNTAIN ROAD, SUITE 200, SAN DIEGO, CA, USA, 92130
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.